Less Invasive Ventricular Enhancement^® (LIVE^®)

President and Chief Executive Officer

With a 30-year career rooted in heart failure, structural heart, interventional cardiology and cardiac surgery, and proven success in fundraising, corporate strategy, market development and physician relationship-building, Jim Dillon serves as President and CEO of BioVentrix. He joined the company in April 2021, with the goal of building the company into a high-performance heart failure therapy company. Prior to joining BioVentrix, he co-founded Reprieve Cardiovascular, an innovator in therapy for acute decompensated heart failure (ADHF), and served as its CEO and as a Board Director. Under his leadership, the company completed first-in-human clinical, achieved FDA Breakthrough Therapy Designation, and secured Series A financing. Previously, he held a series of leadership positions in corporate strategy and sales at St. Jude Medical, driving market development, new technology adoption, capital/consumable sales strategies, and high-performance commercial teams. Prior to St. Jude Medical, Jim held senior executive sales and marketing positions with Abiomed, as well as, was a key contributor to several start-ups’ acquisition and exits; VNUS Medical Technologies (acquired by Covidien), Perclose (acquired by Abbott), Heart Technologies Inc. (acquired by Boston Scientific), and Devices for Vascular Intervention (acquired by Eli Lilly).

Chief Operating Officer

Steve Chartier joined BioVentrix in December 2021 as the company’s Chief Operating Officer (COO), bringing with him over 25 years of proven senior leadership experience managing global regulatory strategy, clinical development, and operations for emerging and established medical device and biotechnology companies. Before joining the Company, Mr. Chartier served as Vice President of Global Clinical Affairs at Sirtex Medical Limited, designing and executing clinical studies and clinical operations for a leading manufacturer of target liver cancer therapies. Prior to this time, he served as the CEO and President at Cardiovascular Clinical Sciences Foundation, a prominent CRO providing clinical trial management for cardiovascular studies. Previously, Mr. Chartier served as the Vice President of Regulatory, Quality and Clinical Affairs at Anika Therapeutics directing clinical development and global regulatory channels. Mr. Chartier also served as Chief Operating Officer for Infraredx, Inc. for many years leading the global regulatory, quality, manufacturing and clinical development strategy for a novel cardiac intravascular imaging technology mapping coronary artery disease.

Chief Medical Officer

Dr. Ben-Yehuda joined BioVentrix in 2023 as the company’s Chief Medical Officer. He is a distinguished clinical cardiologist and clinical trialist with more than 25 years’ experience in the treatment of cardiac patients with coronary disease, myocardial infarction, and heart failure. He is currently Professor of Medicine, University of California, San Diego (UCSD). He is also the Editor-in-Chief of Coronary Artery Disease and Deputy Editor of Structural Heart: The Journal of the Heart Team, both peer-reviewed journals.   

Previously, Dr. Ben-Yehuda was the Executive Director of the Clinical Trials Center (CTC) at the Cardiovascular Research Foundation (CRF), one of the world's leading nonprofit organizations specializing in interventional cardiology innovation, research, and education, and Vice President, Cardiovascular Clinical Trials, at Gilead Sciences.

Dr. Ben-Yehuda has personally authored and co-authored over 200 peer-reviewed publications and is the recipient of multiple awards including Top Abstract, TCT Conference 2017, UCSD Department of Medicine Teaching Awards, and Sackler Faculty Prize for Excellence for his MD Thesis.

Board Chairman, BioVentrix

CEO and member of the board of directors of Axonics, Inc.

President and CEO, BioVentrix

Taglich Brothers Investment Banking

Member of the board of directors at BioLife Solutions, Inc.

Founding partner and chairman of Richmond Brothers, Inc.

Chief Operating Officer of Axonics, Inc.

President of the Heart Failure Association of the ESC